TY  - BOOK
AU  - Ghosh, Raktim K
TI  - Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. [Review]
SN  - 1175-3277
PY  - 2021///
KW  - *Cardiovascular Diseases/co [Complications]
KW  - *Colchicine/tu [Therapeutic Use]
KW  - *Gout Suppressants/tu [Therapeutic Use]
KW  - *Gout/dt [Drug Therapy]
KW  - *Gout/et [Etiology]
KW  - Colchicine/ae [Adverse Effects]
KW  - COVID-19
KW  - Febuxostat/ae [Adverse Effects]
KW  - Febuxostat/tu [Therapeutic Use]
KW  - Gout Suppressants/ae [Adverse Effects]
KW  - Humans
KW  - Hyperuricemia/dt [Drug Therapy]
KW  - Hyperuricemia/et [Etiology]
KW  - Pandemics
KW  - MedStar Union Memorial Hospital
KW  - Journal Article
KW  - Review
N1  - Available online from MWHC library: 2001 - 2009
N2  - Hyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials, and COLCORONA trial which will shed light on its utility in COVID-19. Our aim is to review the CV use of colchicine beyond pericardial diseases, as well as CV outcomes of the available gout therapies, including allopurinol and febuxostat. The CARES trial and its surrounding controversies, which lead to the US FDA 'black box' warning on febuxostat, in addition to the recent FAST trial which contradicts this and finds febuxostat to be non-inferior, are discussed in this paper
UR  - https://dx.doi.org/10.1007/s40256-020-00459-1
ER  -